The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Polyneuropathy of different etiologies is often associated with pain. The standard treatment of this pain is anticonvulsants or antidepressants, but none of these treatment are effective or tolerable for all patients. Levetiracetam is a newer anticonvulsant and it is the hypothesis is that it could relieve neuropathic pain in polyneuropathy. This is a randomised, double-blind, placebo-controlled, cross-over trial on the effect of levetiracetam 3.000 mg/day on pain in polyneuropathy
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
age 20 to 0 years
painful symptoms of polyneuropathy for at least 6 months
confirmed diagnosis of polyneuropathy
baseline pain score of 4 or more (0 to 10 point scale)
pain at least 4 days a week
adequate anticonceptive treatment for women with childbearing potential
other cause of pain
previous allergic reactions towards levetiracetam
known adverse drug reactions on levetiracetam
inability to follow study protocol
treatment with antidepressants, other anticonvulsants or opioids